IGF::OT::IGF SBIR TOPIC 347 PHASE I

癌症是美国第二大常见死因，然而，如果及早发现，死亡率往往会大大降低。在癌症的早期检测中，一个有希望的方法是识别肿瘤生物标记物。识别组织中的生物标记物比循环生物标记物更有价值，因为它们伴随着空间信息，并有可能评估细胞类型和标记物的相互作用。目前，在福尔马林固定、石蜡包埋的组织切片中，用免疫组织化学方法原位检测生物标记物是临床上最常用的方法。然而，生物标志物定位的分辨率有限，这限制了定量分析。免疫荧光已被广泛应用于样品的自体荧光和低限检测。露娜建议开发一种等离子体金属纳米粒子增强荧光免疫分析试剂盒，用于肿瘤生物标志物的识别和定量。金属纳米微粒将近红外染料的荧光增强到5000倍以上，从而极大地提高了载玻片分析的灵敏度和对atmool范围的LOD。露娜的试剂盒保存非常稳定，使用非常简单，并且不会改变目前的检测格式和程序。

Cancer is the second most common cause of death in the United States, however, the mortality rate is often greatly reduced by early detection. One promising approach in the early detection of cancer is to identify tumor biomarkers. Identification of biomarkers in tissues can have more value than circulating biomarkers as they are accompanied by spatial information, and the possibility to assess the interaction of cell types and markers. Currently, measuring biomarkers in-situ in formalin-fixed, paraffin-embedded tissue sections by immonohistochemistry is the most common method in clinic. However, the resolution of biomarker localization is limited which restricts quantitative analysis. Immunofluorescence has been widely used in autoflurenscence of specimen and the low limit. luna proposes to develop a plasmonic metal nanoparticle enhanced fluorescense immunoassay kit for tumor biomarker identification and quantificcation. The NIR dye fluorescence is enhanced by metal noanoparticles to more than 5000 fold and thus highly increase the slide assay sensitivity and LOD to the attomolar range. Luna's kit is highly stable to keep and very simple to use and does not alter the current assay format and procedures.